Literature DB >> 28371244

Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up.

Judith Grogan1, Ruta Gupta1,2,3, Kate L Mahon1,4, Phillip D Stricker5, Anne-Maree Haynes1, Warick Delprado6,7, Jennifer Turner6,7, Lisa G Horvath1,3,4, James G Kench1,2,3.   

Abstract

OBJECTIVE: To assess the relationship between the International Society of Urological Pathology (ISUP) 2014 grading system, biochemical recurrence (BCR) and clinical recurrence (CLR) after radical prostatectomy (RP), to determine whether the 2014 ISUP grading system is a better predictor of survival compared with the previous Gleason scoring systems, and to investigate whether incorporation of the tertiary pattern/grade into the ISUP scoring system significantly improves its efficacy. PATIENTS AND METHODS: A total of 635 RP cases (1991-1999) were identified from a database at a single institution. A histopathology review was performed to re-grade the cases as per the ISUP 2014 grading system. All relevant clinicopathological data and clinical follow-up (median [range] 15.25 [0.3-26] years) were obtained. Log-rank, Kaplan-Meier, Cox regression and Harrell's concordance c-indices analyses were performed.
RESULTS: At a median follow-up of 15 years, 276 patients (44%) had BCR and 41 (7%) had CLR. Grade Groups 1, 2, 3, 4 and 5 were seen in 112 (18%), 307 (48%), 129 (20%), 33 (5%) and 54 patients (9%), respectively: 337 (53%) were upgraded, while 70 (11%) were downgraded compared with the 1992 Gleason system. Grade Group (hazard ratio [HR] 4.9; P < 0.001) and preoperative prostate-specific antigen (PSA) level (HR 1.4; P < 0.001) were independent predictors of BCR. Only Grade Group 5 (HR 12.3; P = 0.02), preoperative PSA (HR 1.6; P < 0.001), stage pT3b (HR 3.1; P = 0.03) and pT4 (HR 12.4; P < 0.001) independently predicted CLR. Harrell's c-indices showed that the 2014 ISUP grading system was a significantly better predictor of BCR and CLR as well as prostate cancer-specific death, compared with the 2005 ISUP modified Gleason system. The replacement of the secondary pattern by the tertiary pattern did not alter the prognostic efficacy of the ISUP 2014 grading system.
CONCLUSIONS: The ISUP 2014 grading system is a significant independent predictor of both BCR and CLR, outperforming the 2005 ISUP modified Gleason system. This classification system has the potential to influence clinical decision-making after RP.
© 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #ProstateCancer; biochemical recurrence; clinical recurrence; grading; radical prostatectomy

Mesh:

Year:  2017        PMID: 28371244     DOI: 10.1111/bju.13857

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  10 in total

1.  The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature.

Authors:  A Offermann; M C Hupe; V Sailer; A S Merseburger; S Perner
Journal:  World J Urol       Date:  2019-04-02       Impact factor: 4.226

2.  The 2014 ISUP grade group system: the Holy Grail or yet another hype?

Authors:  Daimantas Milonas; Steven Joniau
Journal:  World J Urol       Date:  2020-05-03       Impact factor: 4.226

3.  The Impact of Pathologic Upgrading of Gleason Score 7 Prostate Cancer on the Risk of the Biochemical Recurrence after Radical Prostatectomy.

Authors:  Juhyun Park; Sangjun Yoo; Min Chul Cho; Min Hyun Cho; Chang Wook Jeong; Ja Hyeon Ku; Cheol Kwak; Hyeon Hoe Kim; Hyeon Jeong
Journal:  Biomed Res Int       Date:  2018-04-30       Impact factor: 3.411

4.  Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review.

Authors:  David Thurtle; Sabrina H Rossi; Brendan Berry; Paul Pharoah; Vincent J Gnanapragasam
Journal:  BMJ Open       Date:  2019-06-22       Impact factor: 2.692

5.  Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model.

Authors:  David R Thurtle; David C Greenberg; Lui S Lee; Hong H Huang; Paul D Pharoah; Vincent J Gnanapragasam
Journal:  PLoS Med       Date:  2019-03-12       Impact factor: 11.069

6.  Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality.

Authors:  Ruth Pidsley; Dilys Lam; Wenjia Qu; Timothy J Peters; Phuc-Loi Luu; Darren Korbie; Clare Stirzaker; Roger J Daly; Phillip Stricker; James G Kench; Lisa G Horvath; Susan J Clark
Journal:  Clin Transl Med       Date:  2022-10

7.  Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer.

Authors:  Berna Demircan Tan; Turgay Turan; Burcu Yucel; Sedef Altundag Kara; Seda Salman Yilmaz; Asif Yildirim
Journal:  Medeni Med J       Date:  2020-06-30

8.  Race, tumor location, and disease progression among low-risk prostate cancer patients.

Authors:  Justin G Mygatt; Jennifer Cullen; Samantha A Streicher; Huai-Ching Kuo; Yongmei Chen; Denise Young; William Gesztes; Grant Williams; Galen Conti; Christopher Porter; Sean P Stroup; Kevin R Rice; Inger L Rosner; Allen Burke; Isabell Sesterhenn
Journal:  Cancer Med       Date:  2020-01-21       Impact factor: 4.452

9.  Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading.

Authors:  Lars Egevad; Daniela Swanberg; Brett Delahunt; Peter Ström; Kimmo Kartasalo; Henrik Olsson; Dan M Berney; David G Bostwick; Andrew J Evans; Peter A Humphrey; Kenneth A Iczkowski; James G Kench; Glen Kristiansen; Katia R M Leite; Jesse K McKenney; Jon Oxley; Chin-Chen Pan; Hemamali Samaratunga; John R Srigley; Hiroyuki Takahashi; Toyonori Tsuzuki; Theo van der Kwast; Murali Varma; Ming Zhou; Mark Clements; Martin Eklund
Journal:  Virchows Arch       Date:  2020-06-15       Impact factor: 4.064

10.  Prostate cancer grading, time to go back to the future.

Authors:  Lars Egevad; Brett Delahunt; David G Bostwick; Liang Cheng; Andrew J Evans; Troy Gianduzzo; Markus Graefen; Jonas Hugosson; James G Kench; Katia R M Leite; Jon Oxley; Guido Sauter; John R Srigley; Pär Stattin; Toyonori Tsuzuki; John Yaxley; Hemamali Samaratunga
Journal:  BJU Int       Date:  2020-11-27       Impact factor: 5.588

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.